Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.
Chandrasekhar J, Baber U, Sartori S, Faggioni M, Aquino M, Kini A, Weintraub W, Rao S, Kapadia S, Weiss S, Strauss C, Toma C, Muhlestein B, DeFranco A, Effron M, Keller S, Baker B, Pocock S, Henry T, Mehran R. Chandrasekhar J, et al. Among authors: effron m. Catheter Cardiovasc Interv. 2017 Mar 1;89(4):629-637. doi: 10.1002/ccd.26606. Epub 2016 May 24. Catheter Cardiovasc Interv. 2017. PMID: 27152497
Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study.
Makkar R, Goff B, Eigler N, Sebastian M, Fischell T, Barr L, D'Haem C, Shah PK, Effron MB, Litvack F. Makkar R, et al. Among authors: effron mb. Catheter Cardiovasc Interv. 1999 Dec;48(4):430-4. doi: 10.1002/(sici)1522-726x(199912)48:4<430::aid-ccd20>3.0.co;2-g. Catheter Cardiovasc Interv. 1999. PMID: 10559827
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. Tcheng JE, et al. Among authors: effron mb. Circulation. 2003 Sep 16;108(11):1316-23. doi: 10.1161/01.CIR.0000087601.45803.86. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939213 Clinical Trial.
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
Kandzari DE, Tcheng JE, Cohen DJ, Bakhai A, Grines CL, Cox DA, Effron M, Stuckey T, Griffin JJ, Turco M, Carroll JD, Fahy M, Mehran R, Stone GW; CADILLAC Investigators. Kandzari DE, et al. Among authors: effron m. Am J Cardiol. 2003 Oct 1;92(7):779-84. doi: 10.1016/s0002-9149(03)00882-8. Am J Cardiol. 2003. PMID: 14516875 Clinical Trial.
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial.
Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Hamankiewicz M, Pluta W, Oldroyd K, Ecollan P, Janssens L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators. Ellis SG, et al. Among authors: effron mb. JACC Cardiovasc Interv. 2009 Oct;2(10):909-16. doi: 10.1016/j.jcin.2009.07.009. JACC Cardiovasc Interv. 2009. PMID: 19850248 Free article. Clinical Trial.
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals.
Herrmann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A, Neuman FJ, Effron MB, Barnathan ES, Topol EJ, Ellis SG; FINESSE Investigators. Herrmann HC, et al. JACC Cardiovasc Interv. 2009 Oct;2(10):917-24. doi: 10.1016/j.jcin.2009.06.018. JACC Cardiovasc Interv. 2009. PMID: 19850249 Free article.
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. Angiolillo DJ, et al. Eur Heart J. 2011 Apr;32(7):838-46. doi: 10.1093/eurheartj/ehq494. Epub 2011 Jan 20. Eur Heart J. 2011. PMID: 21252171 Free PMC article. Clinical Trial.
139 results